Who We Are
What We Do
Corporate Responsibility
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals Announces Approval of Insulin Glargine in Thailand
Gan & Lee Pharmaceuticals Announces Approval of Insulin Glargine in Thailand

Beijing, China, October 18, 2022 - Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) is pleased to announce its insulin glargine product has been approved by the TFDA for the treatment of diabetes.


Thailand is one of the 39 member countries of the International Diabetes Federation Western Pacific Region (IDF-WPR). According to the International Diabetes Federation Atlas 10th edition, as of 2021, about 6.1 million adults (aged 20 to 79) in Thailand are living with diabetes with a prevalence of 11.6%1. Thailand is a member and co-founder of the Association of Southeast Asian Nations(ASEAN), as well as a member of the Asia-Pacific Economic Cooperation (APEC), the World Trade Organization (WTO) and the International Cooperation Organization for Drug Certification (PIC/S). As such, Thailand is considered quite highly in the Asia-Pacific region. The approval reflects that Gan & Lee products meet the standard of international drug certification.


3mL insulin glargine penfill produced by Gan & Lee can be used in combination with the Gan & Lee insulin pen approved in Thailand earlier. It will provide a safe and effective treatment option for people with diabetes in Thailand.


This approval has sped up the globalization of Gan & Lee, which is conducive to consolidating the company's position in the diabetes field. It is expected that the market share of Gan & Lee’s insulin glargine can be increased in the Southeast Asia, laying the foundation for global market expansion.



1. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).


In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. 

Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号
Our websites


I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.